Table 3

Characteristics of patients treated with adoptive transfer of cultured TALsa

Patient no.Age (yrs)/SexPSOrigin of TALsNo. of transferred cells (× 109)% Positive cells in transferred cellsTNF-α release (pg/ml)RouteClinical responseSurvival time (days)
CD3CD4CD8CD16AutoMKN28MKN45
150/F1As4.897.919.078.23.945610223IPNC661
279/F1As4.098.112.386.82.028924642IPMRb621
356/F1As1.097.315.282.13.0ND1225IPPD347
472/F2As2.197.349.048.94.6562434IPPD280
576/F2As0.990.126.962.78.92209867IPMRc192
668/F1PD363
771/M1Pl0.996.441.144.53.5ND5521IVPD345
879/F1As0.997.324.573.62.1221010IPPD787
950/M1As1.298.133.961.41.1ND98111IPPD439
1067/F1As4.689.944.545.29.3233423IPPD451
1161/F2PD190
1270/M2As3.691.123.477.28.9ND7522IPNC154
1371/F1PD367
1449/F1As2.595.345.352.12.3321100122IPPD429
1551/F2LN1.096.134.160.14.9ND5112IVNC388
1672/M1LN2.092.121.570.15.9522214IVPD621
1772/F1As3.096.519.178.22.521511645IPNC664
1871/M1As1.291.542.150.10.9ND12055IPPD367
1970/F1As3.597.122.571.04.5ND251151IPPD395
2051/M2LN4.591.135.156.18.9597155IVPD160
2178/M1As5.191.522.167.19.0145121198IPNC283
2265/M1As4.198.140.157.41.9214518IPPD369
  • a Except for patients 6, 11, and 13, patients with gastric cancer were treated with adoptive transfer of TALs via i.p. (IP) or i.v. (IV) infusion. Autologous TALs isolated from malignant ascites (As), pleural effusions (Pl), or metastatic lymph nodes (LN) were expanded by repeated stimulation with autologous tumor cells in low-dose recombinant IL-2. The phenotypes of cultured TALs were analyzed by flow cytometry. To study the reactivity of cultured TALs against autologous tumor cells (Auto) and allogeneic gastric cancers (MKN28 and MKN45), TNF-α release assay from TALs was performed. F, female; M, male; PS, performance status; ND, not determined.

  • b Diminished ascites, class V→I.

  • c Diminished ascites, class V→II.